Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

USA - NASDAQ:LXRX - US5288723027 - Common Stock

1.22 USD
+0.13 (+11.93%)
Last: 9/18/2025, 8:00:39 PM
1.23 USD
+0.01 (+0.82%)
After Hours: 9/18/2025, 8:00:39 PM
Fundamental Rating

3

Taking everything into account, LXRX scores 3 out of 10 in our fundamental rating. LXRX was compared to 540 industry peers in the Biotechnology industry. LXRX may be in some trouble as it scores bad on both profitability and health. LXRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LXRX has reported negative net income.
In the past year LXRX has reported a negative cash flow from operations.
LXRX had negative earnings in each of the past 5 years.
In the past 5 years LXRX always reported negative operating cash flow.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

LXRX's Return On Assets of -53.47% is in line compared to the rest of the industry. LXRX outperforms 47.78% of its industry peers.
LXRX has a Return On Equity of -93.19%. This is comparable to the rest of the industry: LXRX outperforms 47.41% of its industry peers.
Industry RankSector Rank
ROA -53.47%
ROE -93.19%
ROIC N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

LXRX's Gross Margin of 99.18% is amongst the best of the industry. LXRX outperforms 97.78% of its industry peers.
In the last couple of years the Gross Margin of LXRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LXRX has more shares outstanding
LXRX has more shares outstanding than it did 5 years ago.
LXRX has a better debt/assets ratio than last year.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

LXRX has an Altman-Z score of -10.76. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.76, LXRX is not doing good in the industry: 74.07% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.43 indicates that LXRX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.43, LXRX is doing worse than 71.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z -10.76
ROIC/WACCN/A
WACC10.49%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.16 indicates that LXRX has no problem at all paying its short term obligations.
With a Current ratio value of 4.16, LXRX perfoms like the industry average, outperforming 47.04% of the companies in the same industry.
LXRX has a Quick Ratio of 4.16. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX's Quick ratio of 4.16 is in line compared to the rest of the industry. LXRX outperforms 48.33% of its industry peers.
Industry RankSector Rank
Current Ratio 4.16
Quick Ratio 4.16
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.69% over the past year.
LXRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 1488.26%.
The Revenue for LXRX have been decreasing by -37.35% on average. This is quite bad
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.88%
Revenue 1Y (TTM)1488.26%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%1652.64%

3.2 Future

LXRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.78% yearly.
Based on estimates for the next years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 73.16% on average per year.
EPS Next Y62.83%
EPS Next 2Y24.75%
EPS Next 3Y18.64%
EPS Next 5Y12.78%
Revenue Next Year357.76%
Revenue Next 2Y4.9%
Revenue Next 3Y35.41%
Revenue Next 5Y73.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

LXRX's earnings are expected to grow with 18.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.75%
EPS Next 3Y18.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (9/18/2025, 8:00:39 PM)

After market: 1.23 +0.01 (+0.82%)

1.22

+0.13 (+11.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners76.48%
Inst Owner Change11.41%
Ins Owners0.86%
Ins Owner Change0.15%
Market Cap443.35M
Analysts80
Price Target2.81 (130.33%)
Short Float %8.04%
Short Ratio10.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.13%
Min EPS beat(2)29.61%
Max EPS beat(2)112.65%
EPS beat(4)3
Avg EPS beat(4)41.42%
Min EPS beat(4)-7.28%
Max EPS beat(4)112.65%
EPS beat(8)7
Avg EPS beat(8)23.99%
EPS beat(12)9
Avg EPS beat(12)13.92%
EPS beat(16)13
Avg EPS beat(16)12.01%
Revenue beat(2)1
Avg Revenue beat(2)234.48%
Min Revenue beat(2)-12.42%
Max Revenue beat(2)481.39%
Revenue beat(4)2
Avg Revenue beat(4)182.32%
Min Revenue beat(4)-41.43%
Max Revenue beat(4)481.39%
Revenue beat(8)2
Avg Revenue beat(8)66.06%
Revenue beat(12)3
Avg Revenue beat(12)55.44%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.59%
PT rev (3m)6.59%
EPS NQ rev (1m)2.63%
EPS NQ rev (3m)17.78%
EPS NY rev (1m)40.11%
EPS NY rev (3m)31.41%
Revenue NQ rev (1m)76.64%
Revenue NQ rev (3m)18.48%
Revenue NY rev (1m)268.37%
Revenue NY rev (3m)199.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.59
P/FCF N/A
P/OCF N/A
P/B 3.43
P/tB 5.22
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.16
BVpS0.36
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.47%
ROE -93.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.18%
FCFM N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score6
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 129.52%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.16
Quick Ratio 4.16
Altman-Z -10.76
F-Score6
WACC10.49%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.88%
EPS Next Y62.83%
EPS Next 2Y24.75%
EPS Next 3Y18.64%
EPS Next 5Y12.78%
Revenue 1Y (TTM)1488.26%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%1652.64%
Revenue Next Year357.76%
Revenue Next 2Y4.9%
Revenue Next 3Y35.41%
Revenue Next 5Y73.16%
EBIT growth 1Y39.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.04%
OCF growth 3YN/A
OCF growth 5YN/A